Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy.
Apurinic/Apyrimidinic Endonuclease 1
C-Type Lectin Domain Family 4 Member M
Cisplatin
Platinum chemotherapy
Journal
Archives of Razi Institute
ISSN: 2008-9872
Titre abrégé: Arch Razi Inst
Pays: Iran
ID NLM: 101549567
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
25
10
2022
accepted:
28
10
2022
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
This study aimed to detect the levels of apurinic/apyrimidinic endonuclease 1 (APE1) gene expression and C-type lectin domain family 4 member M (CLEC4M) and their association with cisplatin chemotherapy in lung cancer patients. Overall, 105 individuals who attended the Al-Amal National Hospital for Cancer Management, Baghdad, Iraq, were enrolled in the study and divided into three equal groups. The groups included the patients newly diagnosed with lung cancer, cancer patients who received cisplatin, and the healthy control group. All study groups were subjected to the sampling of the venous blood for molecular analysis by real-time polymerase chain reaction (RT-PCR) to detect the APE1 gene and enzyme-linked immunosorbent assay (ELISA) for serological testing to measure the concentration of CLEC4M protein. Significantly, the values of both cancer groups were higher than those reported in the control group. The relative index revealed a significant difference in the mean fold change level of APE1 in the newly diagnosed group (3 fold) and cisplatin therapy patients group (2 fold), compared to the control group (
Identifiants
pubmed: 38028841
doi: 10.22092/ARI.2022.360397.2578
pii: ARI-78-3
pmc: PMC10657964
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Endonucleases
EC 3.1.-
DNA-(Apurinic or Apyrimidinic Site) Lyase
EC 4.2.99.18
CLEC4M protein, human
0
Receptors, Cell Surface
0
Cell Adhesion Molecules
0
Lectins, C-Type
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
963-972Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Biochem Biophys Res Commun. 2012 Jul 20;424(1):34-9
pubmed: 22713458
Cancer Med. 2018 Sep;7(9):4406-4419
pubmed: 30109782
Int J Cancer. 2019 Feb 15;144(4):755-766
pubmed: 30259975
Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86
pubmed: 25107571
Genes Dis. 2019 Apr 05;6(2):176-184
pubmed: 31194025
Med Oncol. 2017 Apr;34(4):48
pubmed: 28215024
Biol Chem. 2009 Mar;390(3):191-214
pubmed: 19166318
J Exp Clin Cancer Res. 2019 Jul 15;38(1):309
pubmed: 31307523
J Thorac Oncol. 2016 May;11(5):613-638
pubmed: 27013409
Oncol Lett. 2020 Mar;19(3):1711-1720
pubmed: 32194663
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Clinics (Sao Paulo). 2018 Sep 06;73(suppl 1):e478s
pubmed: 30208165
Cell Death Dis. 2021 May 18;12(6):503
pubmed: 34006852
PLoS One. 2014 Sep 04;9(9):e106485
pubmed: 25188410
Mol Med Rep. 2020 Sep;22(3):2245-2252
pubmed: 32705212
J Clin Oncol. 2005 May 1;23(13):3125-37
pubmed: 15860872
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
Int Rev Immunol. 2014 Jan;33(1):54-66
pubmed: 24156700
Front Oncol. 2020 Jul 28;10:1256
pubmed: 32850380
Oncotarget. 2016 Nov 22;7(47):77482-77494
pubmed: 27813497
Front Genet. 2020 Aug 28;11:978
pubmed: 33005178
Carcinogenesis. 2003 Mar;24(3):511-5
pubmed: 12663512
PLoS One. 2013 Jul 16;8(7):e68467
pubmed: 23874636
Int J Mol Sci. 2021 Feb 17;22(4):
pubmed: 33671279
Int J Mol Sci. 2019 Aug 24;20(17):
pubmed: 31450627
ACS Appl Mater Interfaces. 2020 Mar 25;12(12):13634-13643
pubmed: 32129072
Int J Cancer. 2015 Feb 1;136(3):699-708
pubmed: 24895230
Int J Mol Sci. 2019 Mar 09;20(5):
pubmed: 30857282
Sci Rep. 2020 Jan 8;10(1):28
pubmed: 31913336
Cell Biochem Funct. 2015 Apr;33(3):101-12
pubmed: 25790058
Oncotarget. 2019 Jan 08;10(3):383-394
pubmed: 30719231
J Cancer. 2019 Oct 19;10(25):6374-6383
pubmed: 31772670
Res Microbiol. 2011 Jan;162(1):19-26
pubmed: 20863882
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Reprod Sci. 2021 Sep;28(9):2592-2601
pubmed: 33761125
Oncotarget. 2015 Jan 20;6(2):584-5
pubmed: 25655644